Pancreatic Cancer Awareness Month 2026: what are the warning signs, and how is research changing care?

Pancreatic cancer accounts for a small share of cancer diagnoses in the United States but a much larger share of cancer deaths. Pancreatic Cancer Awareness Month, observed every November, focuses attention on that gap through earlier recognition, better understanding of risk, and wider access to research. In 2026, the month arrives during a period of measurable progress, with new treatment options that came directly from clinical trials.

World Pancreatic Cancer Day, the international focal point of the month, falls on Thursday, November 19, 2026, when supporters display purple, the color of pancreatic cancer awareness.

What is pancreatic cancer?

The pancreas is an organ about six inches long that sits deep in the upper abdomen, behind the stomach. It has two jobs. Most of it makes digestive enzymes, proteins that help break down food. Small clusters of cells make hormones, including insulin, which helps control blood sugar.

Pancreatic cancer begins when cells in the pancreas grow out of control. The type matters, because the two main forms behave differently and are treated differently:

• Pancreatic ductal adenocarcinoma (PDAC) starts in the cells lining the small tubes, or ducts, that carry digestive enzymes. It makes up about nine in ten cases and is what most people mean by “pancreatic cancer.”
• Pancreatic neuroendocrine tumors start in the hormone-making cells. They are much less common, often grow more slowly, and generally have a better outlook.

Pancreatic cancer is the third leading cause of cancer death in the United States, behind lung and colorectal cancer, and some experts project it could become the second in the coming years.

Survival depends heavily on when the cancer is found. Overall, roughly one in eight people diagnosed live at least five years. When the cancer is found while still confined to the pancreas, a little more than four in ten people live five years, compared with about three in a hundred once it has spread to distant organs. These figures describe people diagnosed several years ago, so they do not yet reflect the newest treatments.

Over recent decades, research has steadily improved survival for many cancer types. Progress against pancreatic cancer has been slower, which is why this month emphasizes earlier detection and research participation.

Why is pancreatic cancer often found late?

About half of pancreatic cancers are diagnosed only after they have spread to distant organs. Three factors explain why. First, the pancreas sits behind other organs, so a small tumor cannot be felt during a routine exam and is hard to see clearly on standard imaging. Second, early pancreatic cancer usually causes no symptoms, and early symptoms are often vague.

Third, there is no screening test recommended for people at average risk. The federal preventive services panel advises against screening adults who have no symptoms, because studies have not shown that screening the general population saves lives, and false alarms can lead to unnecessary and risky procedures. Readers may recognize a similar challenge with ovarian cancer, another cancer without a population screening test. The recommendation does not apply to people with a strong family history or certain inherited gene changes, covered in the next section.

Warning signs of pancreatic cancer

When symptoms appear, they can include:

• Jaundice, a yellowing of the skin or the whites of the eyes, often without pain
• Dark urine, pale or greasy stools, and itchy skin, which often accompany jaundice
• Pain in the upper abdomen that may spread to the back
• Unexplained weight loss and loss of appetite
• New diabetes, or diabetes that suddenly becomes harder to control, especially after age 50
• Nausea, fatigue, or an unexplained blood clot

Each of these symptoms has common causes that are far more likely than cancer, such as gallstones or ulcers. The pattern that warrants prompt medical evaluation is a symptom that persists, worsens, or appears together with others, particularly jaundice, unexplained weight loss, or new-onset diabetes without an obvious cause.

Who is at higher risk for pancreatic cancer?

Risk rises with age, and most people diagnosed are over 65. Several risk factors can be changed or managed:

• Smoking is the most important avoidable risk factor. People who smoke have about twice the risk of people who do not, smoking is thought to cause roughly one in four cases, and risk falls after quitting.
• Excess body weight raises risk modestly.
• Heavy alcohol use raises risk mainly by causing chronic pancreatitis, a long-term inflammation of the pancreas.
• Long-standing type 2 diabetes is linked to higher risk.

Other factors cannot be changed. Black Americans have higher rates of pancreatic cancer and higher death rates than other groups. Researchers point to differences in diabetes, smoking, and access to care, although the reasons are not fully understood.

Family history and inherited gene changes

About one in ten pancreatic cancers is linked to an inherited gene change. These include changes in BRCA1 and BRCA2, the genes best known for their role in hereditary breast cancer risk, as well as PALB2, ATM, CDKN2A, and the genes involved in Lynch syndrome and Peutz-Jeghers syndrome. Most people diagnosed with pancreatic cancer, however, have no family history of it.

People with a known high-risk gene change, or with at least two relatives on the same side of the family who had pancreatic cancer, may qualify for surveillance. Surveillance means regular MRI or endoscopic ultrasound, usually starting around age 50 or 10 years younger than the youngest affected relative, at an experienced center. A genetic counselor can help determine whether it applies.

How is pancreatic cancer diagnosed and treated?

Diagnosis usually starts with a CT scan done with a pancreas-specific protocol, which captures detailed images of the pancreas and nearby blood vessels. MRI may add detail, particularly for cysts. Endoscopic ultrasound uses a thin, flexible tube passed through the mouth into the stomach and small intestine. An ultrasound tip at its end sits close to the pancreas and can guide a needle to take a small tissue sample, called a biopsy.

A blood marker called CA 19-9 is often measured, but it cannot diagnose pancreatic cancer on its own. Other conditions can raise it and some people do not produce it, so it is used mainly to track response to treatment.

Doctors then group the cancer by whether surgery is possible:

• Resectable: the tumor can likely be removed with surgery.
• Borderline resectable: the tumor touches nearby blood vessels, so chemotherapy is often given first to make surgery possible.
• Locally advanced: the tumor has grown around major blood vessels, so surgery is not possible, but it has not spread to distant organs.
• Metastatic: the cancer has spread to distant organs such as the liver or lungs.

Surgery offers the only chance of cure but is an option for a minority of patients. The most common operation, the Whipple procedure, removes the head of the pancreas along with part of the small intestine, the gallbladder, and part of the bile duct, then reconnects the digestive tract. Chemotherapy is part of care at every stage, given before or after surgery or as the main treatment. Radiation is used in selected cases. Palliative care, which focuses on pain control, nutrition, and quality of life, can begin at diagnosis alongside treatment and is not the same as hospice care.

National cancer treatment guidelines also recommend two kinds of genetic testing after diagnosis. Germline testing, done on blood or saliva, looks for inherited gene changes that may affect treatment choices and relatives’ risk. Tumor testing, a form of biomarker testing, looks for changes in the cancer’s own DNA that certain targeted medicines can act on. Guidelines call for germline testing for everyone diagnosed, yet a 2026 survey of people with pancreatic cancer found that about one in four had not been offered it. Patients can ask their care team about both tests.

How is research changing pancreatic cancer care?

More than nine in ten pancreatic cancers carry a change in a gene called KRAS. The altered gene acts like a switch stuck on, telling cancer cells to keep growing. For decades, the proteins this gene family makes, called RAS proteins, were considered impossible to target with medicine.

In 2026, United States regulators approved the first medicine designed to block RAS proteins in pancreatic cancer, for adults with metastatic disease who have already received treatment. In the large clinical trial behind the approval, people who received the medicine lived about twice as long, at the median, as people who received chemotherapy. Its role in earlier stages is still being studied.

Earlier in 2026, regulators also approved a wearable device that delivers low-intensity electric fields through patches on the abdomen, used with chemotherapy for locally advanced disease. A new chemotherapy combination for metastatic disease was approved in 2024.

Other approaches remain investigational. Personalized mRNA vaccines, built from the mutations in each patient’s own tumor, produced strong immune responses in about half of participants in a small early study after surgery. A larger randomized study has completed enrollment but has not reported results. Researchers are also testing AI tools that spot subtle early changes on CT scans, early-detection blood tests, and screening for adults over 50 with new-onset diabetes. None of these is yet a recommended screening test.

Why clinical trials matter for pancreatic cancer

National cancer treatment guidelines state that the best management of any patient with cancer is in a clinical trial, and pancreatic cancer advocacy organizations encourage patients to consider trials at diagnosis and at every treatment decision. Participation remains low. In the same 2026 patient survey, fewer than three in ten people had been offered a trial, and older patients were offered trials less often.

Trials exist for people who are newly diagnosed, recovering from surgery, or living with advanced disease. Each trial is reviewed by an institutional review board, an independent committee that protects participants, and every participant goes through informed consent before joining. Reading the consent form carefully helps people understand a study’s purpose, visits, possible risks, and the right to leave at any time.

Frequently asked questions about pancreatic cancer

Is pancreatic cancer hereditary?

Sometimes. About one in ten cases is linked to an inherited gene change, but most people diagnosed have no family history.

Can pancreatic cancer be prevented?

Not with certainty, but not smoking, maintaining a healthy weight, limiting alcohol, and managing diabetes can lower risk.

Will I receive a placebo in a pancreatic cancer trial?

In cancer treatment trials, a placebo is used only when no established treatment exists or is added on top of standard care, so participants are not denied effective treatment. The consent form explains what each group receives.

When is World Pancreatic Cancer Day 2026?

World Pancreatic Cancer Day is observed on the third Thursday of November, which in 2026 is Thursday, November 19.

Pancreatic Cancer Awareness Month 2026 and the path forward

Pancreatic Cancer Awareness Month centers on practical actions: knowing family history, taking persistent symptoms seriously, and asking about genetic testing and clinical trials after a diagnosis.

DecenTrialz is a clinical trial recruitment and pre-screening platform that helps connect people with relevant clinical studies. People share some information about their health, AI matching identifies studies that may fit, and a registered nurse reviews that information before a referral is sent to the research site. The research site team makes the final eligibility decision and handles informed consent and enrollment. DecenTrialz does not diagnose, treat, or give medical advice, and decisions about care belong with a doctor.

People who want to explore pancreatic cancer studies can start at decentrialz.com and bring their questions to their care team. This November, the most useful step may be the simplest: talking with a doctor about any symptom that does not go away.